Monitor upcoming data presentations at EHA (June 11-14) and ASCO (May 29-June 2) for cemsidomide; any positive results could act as catalysts. The revenue decline may cap upside, but the beat and pipeline progress support a neutral-to-positive near-term view.
Price Chart
Executive Summary
C4 Therapeutics reported Q1 2026 results with an EPS beat ($-0.18 vs $-0.26 consensus) and revenue beat ($6.2M vs $4.4M consensus), but total revenue declined 15% YoY from $7.2M. The company highlighted clinical progress for cemsidomide and a new Roche collaboration, with a cash runway to end of 2028. The mixed earnings beat and pipeline catalysts are offset by the revenue decline.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $6.152 million, down from $7.238 million YoY
- Net loss per share $-0.20, improved from $-0.37 YoY
- Beat consensus EPS ($-0.26) and revenue ($4.4M)
- Cash & equivalents $268.3 million; runway to end of 2028
- Phase 2 MOMENTUM trial enrollment on track; Phase 1b combo trial with elranatamab dosed first patient
- New Roche collaboration for degrader-antibody conjugates with $20M upfront
Financial Impact
Revenue declined 15% YoY to $6.2M; net loss narrowed to $25.1M; EPS beat consensus by 30.8%
Risk Factors
- Clinical trial failure or delays for cemsidomide
- Revenue decline trend may continue as collaboration agreements wind down
- Dilution risk from cash burn and potential future capital raises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292648 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 6w ago | 144 | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $2.95 (−30.83%) |
Aug 14, 2026 6w ago | Institutional Cluster | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $2.95 (−30.83%) |
Aug 11, 2026 7w ago | 8-K | $3.62 $4.18 | ▲ +15.47% | ▲ +15.87% | $2.95 (−18.51%) |
Jun 11, 2026 16w ago | Press Release | $3.87 $3.92 | ▲ +1.29% | ▲ +0.86% | $2.95 (−23.77%) |
May 15, 2026 20w ago | 8-K | $3.22 $3.49 | ▲ +8.39% | ▲ +6.77% | $2.95 (−8.39%) |
May 12, 2026 20w ago | 8-K | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $2.95 (−6.94%) |
May 12, 2026 20w ago | Press Release | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $2.95 (−6.94%) |
Apr 9, 2026 25w ago | 8-K | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | $2.95 (+4.24%) |
Apr 9, 2026 25w ago | Press Release | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | $2.95 (+4.24%) |
Mar 25, 2026 27w ago | Press Release | $2.69 $2.70 | ▲ +0.37% | ▲ +0.62% | $2.95 (+9.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access